A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19/ALLO-501

Leukemia Lymphoma

Age Group
0-9 years 10-17 years 18-26 years 27 years and older


Biological treatment cell Biological
UCART19/ALLO-501 follow-up
Trial Summary & Details
Ages: Child, Adult, Older Adult
Condition: Advanced Lymphoid Malignancies

The purpose of this study is to evaluate the long-term safety and efficacy of UCART19/ALLO-501 administration to patients with advanced lymphoid malignancies.

Children's Hospital Los Angeles, Los Angeles, CA
Massachussetts General Hospital, Boston, MA
Children's Hospital of Philadelphia (CHOP), Philadelphia, PA
Hospital of the University of Pennsylvania, Philadelphia, PA
University of Texas Southwestern Medical Center Dallas, TX
University of Texas MD Anderson Cancer Center, Houston, TX
Het Kinderziekenhuis Prinses Elisabeth - UZG, Gent, Belgium
Hôpital Saint-Antoine, PARIS Cedex 12, France
Hôpital Saint-Louis, Paris, France
Hôpital Robert-Debré, Paris, France
Kyushyu University Hospital, Fukuoka, Japan
Hokkaido University Hospital, Sapporo, Japan
Hospital San Juan De Dios, Barcelona, Spain
King's College Hospital NHS Foundation Trust, London, United Kingdom
UCL Great Ormond Hospital, London, United Kingdom
The Christie NHS Foundation Trust, Manchester, United Kingdom